Zentalis Pharmaceuticals, Inc. Cash Flow Statement
ZNTL|2 years of annual SEC 10-K data (FY2024-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 2 fiscal years. All figures from audited SEC 10-K filings.
Zentalis Pharmaceuticals, Inc. used $208M in operating cash flow and negative free cash flow of $208M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -1.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 |
|---|---|---|
| Net Income | -$292.2M | -$236.8M |
| Depreciation & Amortization | $1.4M | $1.4M |
| Operating Cash Flow | -$207.8M | -$163.8M |
| Capital Expenditures | $583.0K | $2.5M |
| Free Cash Flow | -$208.4M | -$166.3M |
| Share Buybacks | $0 | - |